

BARD1 GRANTED ADDITIONAL CHINESE PATENT FOR CORE BARD1 PATENT FAMILY

- **Chinese Divisional Patent granted covering BARD1 Lung Cancer test**
- **Patent provides additional protection for the diagnosis and treatment of lung and colorectal cancer**
- **BARD1 Lung Cancer test now has multiple patents granted in the US, Japan, China and Australia**

Perth, Australia, 24 October 2018: BARD1 Life Sciences Limited (ASX:BD1), a biotechnology company developing non-invasive cancer diagnostics, today announced that on 28th September 2018, the China National Intellectual Property Administration (CNIPA) granted Chinese Patent number 201610347489.9 (Divisional of CN ZL 201180044183.1) entitled 'BARD1 isoforms in lung and colorectal cancer and use thereof'.

This patent family protects the sequence of various BARD1 isoforms specific to lung and colorectal cancer, a method for detecting the presence of the specific BARD1 isoforms, and a method for treating and/or preventing lung cancer and colorectal cancer.

Chinese Patent number 201610347489.9 provides additional important coverage over the parent case CN ZL 201180044183.1 for specific BARD1 isoforms, various methods and kits for use in the detection of the specific BARD1 isoforms, and methods for treatment or prevention of lung and colorectal cancer. This patent was filed in the name of Université De Genève (UNIGE) and Hôpitaux Universitaires de Genève (HUG) on 17 August 2011 and is due to expire on 17 August 2031. BARD1 LSL (via its fully owned subsidiary BARD1AG SA) has licensed the commercial rights to exploit this technology from UNIGE and HUG.

This core patent family now has 6 granted patents in the US, Japan, Japan divisional, China, China divisional and Australia, with other jurisdictions pending. It provides intellectual property protection for the BARD1 Lung Cancer test.

BARD1 recently announced the grant of its first US patent in its second key patent family entitled 'Kits for detecting breast or ovarian cancer in a body fluid sample and use thereof' that expires on 29 July 2032. This patent family provides protection for its lead BARD1 Ovarian Cancer test and new BARD1 Breast Cancer test.

BARD1 CEO Dr Leeearne Hinch said: "BARD1 currently has 5 patent families providing broad protection over its BARD1 biomarkers, methods and uses. Importantly, our patents and patent applications protect our BARD1 autoantibody tests in development for early detection of breast, ovarian and lung cancers in multiple countries. The Company continues to build and maintain patent protection for its technologies and products."

- ENDS -

FOR MORE INFORMATION PLEASE CONTACT:

Peter Gunzburg
Chairman
E peter@bard1.com

Dr Leeearne Hinch
CEO
E leeearne@bard1.com
M +61 400 414 416

ABOUT BARD1 LIFE SCIENCES LTD (BARD1 LSL)

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian-based biotechnology company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1's proprietary technology platform is based on novel tumour markers with potential diagnostic and therapeutic applications across multiple cancers. The pipeline includes BARD1 autoantibody tests in development for early detection of breast, ovarian and lung cancers. Additional diagnostic projects will be evaluated for other cancers. The company also has a cancer vaccine project at research-stage for treatment of cancer. BARD1 is committed to transforming the early detection of cancer to save lives. For more information on BARD1, see www.bard1.com.

ABOUT THE BARD1 INTELLECTUAL PROPERTY PORTFOLIO

BARD1 has established a strong intellectual property position covering various BARD1 DNA and protein sequences, methods of diagnosis and treatment, and use in multiple cancers. The patent portfolio comprises 5 patent families with multiple granted and pending patents across key marketplaces including the US, Europe and Japan.

Figure 1: BARD1 Patent Status

| Patent Family 5 | Title | Granted 10 | Pending 19 | Expiry |
|--------------------|--|------------------------------------|--|--------|
| PCT/FR01/02731 | Truncated BARD1 protein and its diagnostic and therapeutic uses | US, JP | | 2021 |
| PCT/IB2011/053635 | BARD1 isoforms in lung and colorectal cancer and use thereof | US, JP, JP div, IL, CN, CN div, AU | US (divisional), EP, CA, BR, SG, HK | 2031* |
| PCT/IB2011/054194 | Kits for detecting breast or ovarian cancer in a body fluid sample and use thereof | US | US (divisional), EP | 2031* |
| PCT/EP2014/073834 | Lung Cancer Diagnosis | | US, EP, CA, JP, IL, CN, AU, SG, KR, HK | 2034* |
| EP14002398.7 | Novel non-coding RNA, cancer target and compounds for cancer treatment | | US | 2035* |

* Plus any extension of term in the US due to prosecution delay